FAP靶向诊疗在晚期肉瘤中的初步研究:⁶⁸Ga-FAPI-46显像与¹⁷⁷Lu-FAPI-2286治疗
单中心探索性研究纳入6例经治转移性肉瘤患者,比较⁶⁸Ga-FAPI-46与¹⁸F-FDG PET/CT定量参数,并评估¹⁷⁷Lu-FAPI-2286放射配体治疗的安全性和疗效。两种显像定量参数无统计学显著差异,但¹⁸F-FDG显示略高的MTV。治疗耐受良好,无≥3级毒性,3例可评估患者中1例混合缓解、1例稳定、1例进展,中位总生存4个月(95%CI: 0-8.8月)。
要点
- ⁶⁸Ga-FAPI-46与¹⁸F-FDG PET/CT定量参数无显著差异,但FDG的MTV略高。
- ¹⁷⁷Lu-FAPI-2286治疗耐受良好,仅见低级别血液学毒性,无≥3级不良事件。
- 可评估患者中1例混合缓解、1例稳定、1例进展,中位OS为4个月。
核心结论
- ¹⁷⁷Lu-FAPI-2286放射配体治疗在重度经治肉瘤患者中安全、耐受良好,并显示疾病稳定。
- ⁶⁸Ga-FAPI-46 PET/CT对富含FAP肿瘤区域的描绘更优,但肿瘤体积较¹⁸F-FDG PET/CT小。
研究设计与样本
- 单中心探索性研究纳入6例组织学确诊的治疗难治性转移性肉瘤患者,中位年龄29岁。
- 所有患者基线接受⁶⁸Ga-FAPI-46和¹⁸F-FDG PET/CT,随后接受2至4个周期¹⁷⁷Lu-FAPI-2286治疗,每周期3.7-7.4 GBq。
- 采用系列平面和SPECT/CT显像进行器官剂量学评估,PERCIST评估治疗反应,CTCAE v5.0分级毒性。
主要发现
- 基于6例患者的定量影像数据,⁶⁸Ga-FAPI-46与¹⁸F-FDG在SUVmean、SUVmax、MTV/FTV、TLG/TLF和TLR上无统计学显著差异。
- ¹⁸F-FDG显示略高的MTV。
- 治疗耐受良好,无≥3级治疗相关毒性;不良事件限于低级别血液学毒性:2级白细胞减少(n=1)、1级贫血(n=2)、1级血小板减少(n=1)。
- 6例患者中3例在完成随访显像前因疾病进展死亡;3例可评估患者中,1例混合缓解(基于SUVmax和SUVmean下降为PR,基于FTV增加为PD,基于TLF微小变化为SD),1例SD,1例PD。
- 中位总生存期为4个月(95%CI: 0-8.8月)。
关键数值与推荐
- 治疗反应采用PERCIST标准评估。
- 毒性分级依据CTCAE v5.0。
- ¹⁷⁷Lu-FAPI-2286每周期剂量为3.7-7.4 GBq,共2至4个周期。
临床怎么用
- 对于重度经治的晚期转移性肉瘤患者,¹⁷⁷Lu-FAPI-2286放射配体治疗可能是一种安全且耐受良好的选择,可考虑用于疾病稳定。
- ⁶⁸Ga-FAPI-46 PET/CT可用于更优描绘富含FAP的肿瘤区域,但需注意其显示的肿瘤体积可能小于¹⁸F-FDG PET/CT。
局限性
- 单中心探索性研究,样本量小(6例),仅3例可评估治疗反应。
- 3例患者在随访显像前死亡,可能影响疗效评估。
- 需前瞻性多中心研究确认结果并优化FAP靶向诊疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sarcomas are aggressive mesenchymal malignancies with high recurrence rates and poor prognosis, particularly in advanced, metastatic stages where conventional therapies have been exhausted. Fibroblast activation protein (FAP), highly expressed in the tumor microenvironment of sarcomas, presents a promising theranostic target. This study aimed to evaluate the safety and efficacy of ¹⁷⁷Lu-FAPI-2286 radioligand therapy (RLT) in patients with advanced metastatic sarcoma and to compare the diagnostic utility of ⁶⁸Ga-FAPI-46 PET/CT with ¹⁸F-FDG PET/CT in these patients. METHODS: This single-center exploratory study enrolled 6 patients (median age, 29 y) with histologically confirmed treatment-refractory metastatic sarcoma. All patients underwent baseline ⁶⁸Ga-FAPI-46 and ¹⁸F-FDG PET/CT, followed by 2 to 4 cycles of ¹⁷⁷Lu-FAPI-2286 (3.7-7.4 GBq per cycle). Organ-level dosimetry was performed using serial planar and SPECT/CT imaging. Treatment response was evaluated using PET response criteria in solid tumors (PERCIST), and toxicity was graded according to CTCAE v5.0. Quantitative image-derived metrics, including the standardized uptake value (SUV), metabolic tumor volume (MTV), total lesion glycolysis (TLG), FAP expression tumor volume (FTV), total lesion FAP expression (TLF), and tumor-to-liver ratio (TLR) were extracted. RESULTS: On the basis of the quantitative imaging data from the 6 sarcoma patients, there was no statistically significant difference between ⁶⁸Ga-FAPI-46 and ¹⁸F-FDG across the measured parameters (SUV mean , SUV max , MTV/FTV, TLG/TLF, and TLR). However, ¹⁸F-FDG showed slightly higher MTVs. RLT was well-tolerated, with no grade ≥3 treatment-related toxicities observed. Adverse events were limited to low-grade hematological toxicities, including grade 2 leukopenia (n=1), grade 1 anemia (n=2), and grade 1 thrombocytopenia (n=1). Among 6 patients, 3 died due to disease progression before follow-up imaging could be completed. Among the 3 evaluable patients, one patient showed a mixed response pattern with metabolic improvement, but volumetric progression [partial response (PR) based on a decrease in SUV max and SUV mean , progressive disease (PD) based on an increase in FTV, and stable disease (SD) based on minimal change in TLF], another patient showed SD, and the last patient demonstrated PD. The median overall survival was 4 months (95% CI: 0-8.8 mo). CONCLUSION: 177 Lu-FAPI-2286 RLT was safe, well-tolerated, and demonstrated disease stabilization in heavily pretreated sarcoma patients. 68 Ga-FAPI-46 PET/CT provides superior delineation of FAP-rich tumor areas, but smaller tumor volumes compared with 18 F-FDG PET/CT. Prospective multicenter studies are warranted to confirm these findings and optimize FAP-targeted theranostic strategies in sarcoma.
引用
- Jokar N, Juweid ME, Jafari E, et al. FAP-Targeted Theranostics in Advanced Sarcoma: A Pilot Study of ⁶⁸Ga-FAPI-46 Imaging and ¹⁷⁷Lu-FAPI-2286 Therapy. Clin Nucl Med. 2026. PMID: 42080808. doi:10.1097/RLU.0000000000006507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。